首页> 外文期刊>Spine >Preoperative Opioid Weaning Before Major Spinal Fusion Simulated Data, Real-World Insights
【24h】

Preoperative Opioid Weaning Before Major Spinal Fusion Simulated Data, Real-World Insights

机译:术前阿片类药物在主要脊柱融合之前断奶模拟数据,现实世界洞察

获取原文
获取原文并翻译 | 示例
           

摘要

Study Design. Retrospective cohort. Objective. To identify gaps in opioid prescription immediately prior to spinal fusion and to study the effect of such simulated "opioid weaning/elimination" on risk of long-term postoperative opioid use. Summary of Background Data. Numerous studies have described preoperative opioid duration and dose thresholds associated with sustained postoperative opioid use. However, the benefit and duration of preoperative opioid weaning before spinal fusion has not been elaborated. Methods. Humana commercial insurance data (2007-Q1 2017) was used to study primary cervical and lumbar/thoracolumbar fusions. More than 5000 total morphine equivalents in the year before spinal fusion were classified as chronic preoperative opioid use. Based on time between last opioid prescription ( 2-months gap (2G) and >3-months gap (3G). Primary outcome measure was long-term postoperative opioid use (>5000 total morphine equivalents between 3 and 12-mo postoperatively). The effect of "opioid gap" on risk of long-term postoperative opioid use was studied using multiple-variable logistic regression analyses. Results. 17,643 patients were included, of whom 3590 (20.3%) had chronic preoperative opioid use. Of these patients, 41 (1.1%) were in the 3G group and 106 (3.0%) were in the 2G group. In the 2G group, 53.8% patients ceased to have long-term postoperative use as compared with 27.8% in NG group. This association was significant on logistic regression analysis (OR 0.30, 95% CI: 0.20-0.46, P 2-months prior to spinal fusion and less than 14-days' supply had significantly lower risk of long-term postoperative opioid use. We have simulated "opioid weaning" in chronic opioid users undergoing major spinal fusion and our analysis provides an initial reference point for current clinical practice and future clinical studies.
机译:研究设计。回顾性队列研究。客观的确定脊柱融合术前阿片类药物处方的差距,并研究此类模拟“阿片类药物断奶/清除”对术后长期使用阿片类药物风险的影响。背景数据摘要。许多研究描述了术前阿片类药物持续时间和剂量阈值与术后持续使用阿片类药物有关。然而,脊柱融合术前阿片类药物断奶的益处和持续时间尚未阐明。方法。Humana商业保险数据(2007-2017年第一季度)用于研究原发性颈椎和腰椎/胸腰段融合。在脊柱融合术前一年,超过5000个总吗啡当量被归类为术前长期使用阿片类药物。基于最后一次阿片类药物处方之间的时间间隔(2个月间隔(2G)和>3个月间隔(3G)。主要观察指标是术后长期使用阿片类药物(术后3至12个月内,吗啡总当量>5000)。采用多变量logistic回归分析研究了“阿片间隙”对术后长期使用阿片类药物风险的影响。后果纳入17643例患者,其中3590例(20.3%)术前长期使用阿片类药物。在这些患者中,3G组41例(1.1%),2G组106例(3.0%)。2G组有53.8%的患者术后停止长期使用,而NG组为27.8%。在逻辑回归分析中,这种关联是显著的(OR 0.30,95%可信区间:0.20-0.46,P 2个月前脊柱融合和少于14天的供应显著降低了术后长期使用阿片类药物的风险。我们模拟了“阿片类药物断奶”我们的分析为目前的临床实践和未来的临床研究提供了一个初始参考点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号